PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL

被引：0
|
作者：
Desai, U. [1 ]
Huang, M. [2 ]
Kirson, N. Y. [1 ]
King, S. [1 ]
Hellstern, M. [1 ]
Schonfeld, S. [1 ]
Birnbaum, H. G. [1 ]
Lee, A. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Biogen, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND45
引用
收藏
页码：A195 / A195
页数：1
相关论文
共 50 条
  • [31] Lymphocyte count reductions in relapsing-remitting multiple sclerosis (RRMS) patients treated with delayed-release dimethyl fumarate: integrated analysis of the placebo-controlled studies
    Fox, R. J.
    Chan, A.
    Gold, R.
    Phillips, J. T.
    Selmaj, K.
    Raghupathi, K.
    Yuan, H.
    O'Gorman, J.
    Novas, M.
    Viglietta, V.
    Kurukulasuriya, N. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 343 - 343
  • [32] Lymphocyte count reductions in relapsing-remitting multiple sclerosis (RRMS) patients treated with delayed-release dimethyl fumarate: integrated analysis of the placebo-controlled studies
    Fox, R. J.
    Chan, A.
    Gold, R.
    Phillips, J. T.
    Selmaj, K.
    Raghupathi, K.
    Yuan, H.
    O'Gorman, J.
    Novas, M.
    Viglietta, V.
    Kurukulasuriya, N. C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S231 - S232
  • [33] An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis
    Valencia-Sanchez, Cristina
    Carter, Jonathan L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) : 1399 - 1405
  • [34] Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
    Fox, Robert J.
    Chan, Andrew
    Gold, Ralf
    Phillips, J. Theodore
    Selmaj, Krzysztof
    Zhang, Ray
    Chang, Ih
    Prada, Claudia
    Ray, Soma
    Mehta, Devangi
    Taylor, Catherine
    Marantz, Jing
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 155 - 155
  • [35] Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
    Fox, R. J.
    Chan, A.
    Gold, R.
    Phillips, J. T.
    Selmaj, K.
    Zhang, R.
    Chang, I.
    Prada, C.
    Ray, S.
    Mehta, D.
    Taylor, C.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 349 - 349
  • [36] COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
    Silva Miguel, L.
    de Sa, J.
    Pinheiro, B.
    Acosta, C.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [37] Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing multiple sclerosis
    Fox, E. J.
    Vasquez, A.
    Grainger, W.
    Ma, T. S.
    von Hehn, C.
    Walsh, J.
    Li, J.
    Zambrano, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 205 - 205
  • [38] Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
    Narapureddy, Bhavya
    Dubey, Divyanshu
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1655 - 1666
  • [39] COMPARATIVE EFFECTIVENESS USING A MATCHING-ADJUSTED INDIRECT COMPARISON BETWEEN DELAYED-RELEASE DIMETHYL FUMARATE AND FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J.
    Edwards, M. R.
    Marantz, J. L.
    VALUE IN HEALTH, 2015, 18 (07) : A750 - A750
  • [40] THE COST-EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE CHILEAN NATIONAL HEALTH FUND (FONASA)
    Noda, C.
    de Anda, J. A.
    Anaya, P.
    Serafini, P.
    Machado, M.
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
12345